PharmaCorp Rx to Pitch Its Vision for Canadian Pharmacy at Top Conference

SASKATOON, Saskatchewan – April 02, 2026 – PharmaCorp Rx Inc. (TSXV: PCRX), a company rapidly carving out a niche in the Canadian pharmacy landscape, is set to step into the investor spotlight later this month. Senior management will present its corporate strategy at the prestigious 2026 Bloom Burton & Co. Healthcare Investor Conference in Toronto on April 21, an event that could prove pivotal for the company’s ambitious growth plans.

The presentation offers a high-profile platform for PharmaCorp to articulate its vision to a discerning audience of American, Canadian, and international investors. The company’s model—acquiring independent pharmacies and empowering pharmacists as equity partners—is a direct response to a fundamental shift occurring within community healthcare across Canada. As it seeks to build a national network under the PharmaChoice Canada banner, this conference provides a crucial opportunity to secure the capital market support necessary to fuel its expansion.

A New Blueprint for Community Pharmacy

At the heart of PharmaCorp's strategy is a unique approach to market consolidation. Unlike traditional corporate takeovers, the company focuses on a partnership model designed to preserve the legacy of independent pharmacies while providing a viable exit for retiring owners. This addresses a growing succession crisis in the sector, where many long-time pharmacists lack a clear path to transition their businesses.

PharmaCorp’s proposition is twofold. For retiring owners, it offers a structured sale process that aims to protect the community relationships and patient trust built over decades. For younger or mid-career pharmacists, it provides a pathway to ownership. By retaining pharmacists as equity partners in their own stores, the model fosters an owner-operator mentality that is often lost in larger chain acquisitions. This structure is intended to maintain high levels of patient care and service continuity, key differentiators for community pharmacies.

Currently operating seven locations, the company has demonstrated a disciplined but aggressive acquisition pace. It closed on three pharmacies in October 2025 and another in August 2025, signaling a clear intent to scale. The company actively solicits discussions with pharmacy owners, positioning itself as a dedicated partner for those navigating the complexities of succession.

The Power of a Strategic Alliance

PharmaCorp's growth is not occurring in a vacuum; it is deeply intertwined with its strategic alliance with PharmaChoice Canada Inc. This partnership is a cornerstone of its business model, providing immediate scale, brand recognition, and operational leverage. PharmaChoice is not a typical corporate chain but a member-owned cooperative representing over 1,000 independent pharmacies, making it the fastest-growing pharmacy group in Canada and the eighth largest in North America.

By rebranding its acquired locations under the PharmaChoice banner, PharmaCorp taps into a network with over $2 billion in annual retail sales. This affiliation grants its pharmacies access to the collective bargaining power, marketing programs, and operational support systems of a major national player. It allows them to compete more effectively on price and services with large corporate chains while retaining the local, community-focused identity that independent pharmacies are known for.

This symbiotic relationship is a key selling point. PharmaCorp gains a turnkey operational framework and a trusted brand, while the PharmaChoice cooperative expands its footprint with new, motivated owner-partners. For investors, this alliance mitigates some of the risks associated with a pure roll-up strategy by integrating acquisitions into a proven and successful national system.

An Investor's Calculus: Growth vs. Profitability

While PharmaCorp's strategic narrative is compelling, investors at the Bloom Burton conference will be scrutinizing the financial metrics that underpin the story. The company's recent performance presents a mixed but intriguing picture. On one hand, its growth trajectory is impressive. Revenue is forecast to grow at 67.3% per year, far outpacing the Canadian market average. The company also reached a significant milestone in the first quarter of 2025, posting its first-ever quarter of positive net income at $254,000.

On the other hand, there are points of concern that management will need to address. Despite the revenue surge, the company's earnings have been on a declining trend, averaging a -15.6% drop annually. Furthermore, its stock has underperformed the broader market over the past year, with a decline of over 17%. This disconnect between the company’s strategic progress and its market valuation is at the core of the investment debate.

However, a deeper look at the balance sheet reveals a company built for expansion, boasting a healthy current ratio of 2.38, which indicates a strong ability to fund its operations and acquisition pipeline. Analyst coverage, though limited, reflects optimism. The consensus recommendation is a "Buy," with a target price of $0.57 suggesting a potential upside of over 30% from its recent trading levels. This suggests that some market watchers believe the current stock price does not fully reflect the company's long-term potential.

The upcoming presentation in Toronto will be management’s opportunity to bridge this gap. They will be tasked with convincing investors that the current earnings trend is a temporary function of its high-growth investment phase and that the strategic acquisitions will soon translate into sustained profitability. How effectively they communicate this message could significantly influence investor sentiment and the company’s ability to finance the next stage of its national expansion.